Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 1

Status

Completed 40Unknown 9Withdrawn 3Terminated 3Recruiting 3Active not recruiting 3

Sponsor Class

OTHER 1NIH 1INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Lymphoid 2CNS 1

Conditions

Oligodendroglioma 1Lymphoma 1Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8 1

Interventions

pembrolizumab 555Specimen Handling 459Carboplatin 446Magnetic Resonance Spectroscopy 427Cyclophosphamide 412Cisplatin 404Gemcitabine 314Radiotherapy 313Bevacizumab 310Paclitaxel 300Biopsy 260Drug Therapy 252Capecitabine 241Oxaliplatin 240fludarabine 236Nivolumab 226venetoclax 225Injections 214Docetaxel 203Fluorouracil 201Dexamethasone 186Radiosurgery 172Rituximab 161Pemetrexed 157durvalumab 144Standard of Care 143atezolizumab 139toripalimab 137tislelizumab 137Leucovorin 137

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Recruiting × Interventional × Procarbazine × Clear all
NCT05675410 2026-05-27

A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab

National Cancer Institute (NCI)

Phase 3 Recruiting
1,875 enrolled
Lymphoid

Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8

NCT07015242 2026-03-24

A Study of the Efficacy and Safety of Lisocabtagene Maraleucel (Liso-cel) as First-Line Therapy in Adults With Transplant-Ineligible Primary Central Nervous System Lymphoma

Juno Therapeutics, Inc., a Bristol-Myers Squibb Company

Phase 2 Recruiting
65 enrolled
Lymphoid

Lymphoma

NCT05331521 2026-02-03

ImproveCodel

University Hospital Heidelberg

Phase 3 Recruiting
406 enrolled
CNS

Oligodendroglioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡